Longevity
Epithalon
40mg
$123.75$165.00
The Collection
Front
✦Third-party tested✦American made✦Ships in 24–48h
Longevity
FOXO4
$146.25$195.00
Strength · 10mg
FOXO4-DRI is a designed peptide researched for its interaction with the p53–FOXO4 pathway in cellular-senescence models.
1
- Bulk
- 5+ vials — 5% · 10+ vials — 10% preferred rate
- Shipping
- Complimentary US shipping over $200
- Payment
- Card · Zelle · Venmo · Cash App
✦
✦
✦
Research Notice
For laboratory research use only. Not for human consumption.
The Dossier
Research Notes
FOXO4-DRI is a synthetic, cell-permeable D-retro-inverso peptide — assembled from D-amino acids in reversed sequence for protease resistance — derived from the forkhead domain of the FOXO4 transcription factor and fused to a cell-penetrating domain. It was designed as a senolytic research tool.
It is a specialized reference for longevity laboratory work, studied for its interaction with the p53–FOXO4 pathway in cellular-senescence models.
Research Focus
- ✦Cellular-senescence and aging models
- ✦Chemotherapy-toxicity models
- ✦Cardiovascular- and endothelial-aging models
- ✦Pulmonary-fibrosis and osteoarthritis models
- ✦Senescent-cell (p53/FOXO4) pathway research
Mechanism
FOXO4-DRI is characterized as a competitive peptide antagonist that disrupts the FOXO4–p53 interaction in senescent cells, binding the p53 transactivation domain and outcompeting endogenous FOXO4.
Liberated p53 is reported to undergo mitochondrial translocation associated with intrinsic apoptotic signaling — a selectivity attributed to the low FOXO4 expression of non-senescent cells.
Molecular Profile
- Molecular weight
- ≈5358 Da
- CAS number
- 2460055-10-9
- Also known as
- FOXO4-DRI, Proxofim, D-retro-inverso peptide
Storage & Handling
Store the lyophilized peptide at −20°C or lower for long-term stability. Reconstituted peptide is aliquoted, kept cold, and used promptly; avoid repeated freeze-thaw cycles.
References
- Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017.
- Bourgeois B, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic FOXO4-DRI. Nat Commun. 2025.
✦Every vial ships with third-party HPLC verification; certificates of analysis are available on request.
Continue Exploring
